Novavax, Inc. (NVAX) Raising Eyebrows Among Investors

Novavax, Inc. (NASDAQ:NVAX) has recently been identified as an interesting stock but more in-depth monitoring is needed for a trade decision. Now trading with a market value of 618.34M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. As the day-to-day narrative ebbs and flows for this company, it is more important than ever to step back and get a bird’s eye view of the fundamental reality under the surface of this story.

Novavax, Inc. (NASDAQ:NVAX) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For NVAX, the company currently has 132.95 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 276.07 million in total assets, balanced by 375.44 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Novavax, Inc. (NVAX) saw -66.23 million in free cash flow last quarter, representing a quarterly net change in cash of -1.59 million. Perhaps most importantly where cash movements are concerned, the company saw about -66.08 million in net operating cash flow.

Novavax, Inc. (NASDAQ:NVAX) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 9.65 million in total revenues. That represents a quarterly year/year change in revenues of 0.70 in sequential terms, the NVAX saw sales decline by -0.07.

But what about the bottom line? After all, that’s what really matters in the end. Novavax, Inc. (NVAX) is intriguing when broken down to its core data. For shareholders, given the total diluted outstanding shares of 336.97 million, this means overall earnings per share of -0.14. Note, this compares with a consensus analyst forecast of -0.11 in earnings per share for its next fiscal quarterly report.

Is Novavax, Inc. (NASDAQ:NVAX) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.49 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Novavax, Inc..

Previous ArticleNext Article

Related Post

Fundamentals in Focus for Petroleo Brasileiro S.A.... Petroleo Brasileiro S.A. - Petrobras (NYSE:PBR) has recently been identified as an interesting stock but more in-depth monitoring is needed for a trad...
Norfolk Southern Corporation (NSC) vs. Invitation ... Norfolk Southern Corporation (NYSE:NSC) and Invitation Homes Inc. (NYSE:INVH) are the two most active stocks in the Railroads industry based on today’...
Choosing Between Ally Financial Inc. (ALLY) and Sa... Ally Financial Inc. (NYSE:ALLY) and Santander Consumer USA Holdings Inc. (NYSE:SC) are the two most active stocks in the Mortgage Investment industry ...
Checking Out the Fundamental Data for B2Gold Corp.... B2Gold Corp. (NYSE:BTG)'s interesting series of developments are underway around the US stock market these days. Now trading with a market value of 3....
Ironwood Pharmaceuticals, Inc. (IRWD): Does This M... Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is one of the active stocks and its unusual movement is raising eyebrows among traders. Now trading with ...